Blueprint Total Liab vs Other Current Liab Analysis
BPMC Stock | USD 102.81 0.42 0.41% |
Blueprint Medicines financial indicator trend analysis is way more than just evaluating Blueprint Medicines Corp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Blueprint Medicines Corp is a good investment. Please check the relationship between Blueprint Medicines Total Liab and its Other Current Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
Total Liab vs Other Current Liab
Total Liab vs Other Current Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Blueprint Medicines Corp Total Liab account and Other Current Liab. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Blueprint Medicines' Total Liab and Other Current Liab is -0.01. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Other Current Liab in the same time period over historical financial statements of Blueprint Medicines Corp, assuming nothing else is changed. The correlation between historical values of Blueprint Medicines' Total Liab and Other Current Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Blueprint Medicines Corp are associated (or correlated) with its Other Current Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Liab has no effect on the direction of Total Liab i.e., Blueprint Medicines' Total Liab and Other Current Liab go up and down completely randomly.
Correlation Coefficient | -0.01 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Other Current Liab
Most indicators from Blueprint Medicines' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Blueprint Medicines Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. At present, Blueprint Medicines' Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 1.12, whereas Issuance Of Capital Stock is forecasted to decline to 0.00.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 7.4M | 16.8M | 51.6M | 54.2M | Depreciation And Amortization | 6.5M | 11.7M | 11.7M | 12.2M |
Blueprint Medicines fundamental ratios Correlations
Click cells to compare fundamentals
Blueprint Medicines Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Blueprint Medicines fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 707.7M | 1.7B | 1.3B | 1.3B | 1.0B | 784.9M | |
Short Long Term Debt Total | 95.9M | 89.6M | 111.4M | 242.5M | 774.1M | 812.8M | |
Other Current Liab | 88.7M | 105.9M | 96.8M | (295.5M) | 128.0M | 134.4M | |
Total Current Liabilities | 106.5M | 130.8M | 149.8M | 183.2M | 214.9M | 225.7M | |
Total Stockholder Equity | 464.4M | 1.5B | 970.7M | 514.7M | 130.6M | 124.1M | |
Other Liab | 47.7M | 35.8M | 28.4M | 437.0M | 502.5M | 527.6M | |
Property Plant And Equipment Net | 111.1M | 101.7M | 120.9M | 115.2M | 115.7M | 63.4M | |
Current Deferred Revenue | 6.2M | 12.6M | 36.6M | 448.6M | 812K | 771.4K | |
Net Debt | (18.0M) | (595.0M) | (98.5M) | 122.7M | 702.8M | 738.0M | |
Retained Earnings | (945.2M) | (631.4M) | (1.3B) | (1.8B) | (2.3B) | (2.2B) | |
Accounts Payable | 4.8M | 4.4M | 8.3M | 2.7M | 4.7M | 3.9M | |
Cash | 113.9M | 684.6M | 209.9M | 119.7M | 71.3M | 67.7M | |
Non Current Assets Total | 190.9M | 790.6M | 698.2M | 303.3M | 240.9M | 236.9M | |
Non Currrent Assets Other | 15.4M | 11.1M | 19.8M | 26.8M | 30.6M | 32.2M | |
Other Assets | 15.4M | 569.3M | 19.8M | 26.8M | 1.0 | 0.95 | |
Cash And Short Term Investments | 548.0M | 1.5B | 1.0B | 1.1B | 710.6M | 656.9M | |
Common Stock Total Equity | 49K | 58K | 59K | 60K | 69K | 41.4K | |
Common Stock Shares Outstanding | 47.8M | 56.2M | 58.5M | 59.6M | 60.6M | 43.6M | |
Liabilities And Stockholders Equity | 707.7M | 1.7B | 1.3B | 1.3B | 1.0B | 784.9M | |
Non Current Liabilities Total | 136.9M | 117.5M | 131.7M | 652.0M | 703.7M | 738.9M | |
Other Current Assets | 379.4M | (655.9M) | (539.5M) | 35.0M | 33.4M | 35.0M | |
Other Stockholder Equity | 1.4B | 2.1B | 2.3B | 2.4B | 2.5B | 1.3B | |
Total Liab | 243.3M | 248.3M | 281.5M | 835.2M | 918.6M | 964.6M | |
Property Plant And Equipment Gross | 111.1M | 101.7M | 146.3M | 146.5M | 154.1M | 161.9M | |
Total Current Assets | 516.8M | 927.8M | 554.0M | 1.0B | 808.4M | 548.0M | |
Accumulated Other Comprehensive Income | (2.5M) | (5.2M) | (4.1M) | (10.4M) | (3.5M) | (3.7M) | |
Short Term Debt | 6.8M | 7.9M | 8.1M | 27.4M | 81.4M | 85.5M | |
Common Stock | 49K | 58K | 59K | 60K | 61K | 43.7K | |
Property Plant Equipment | 38.4M | 34.1M | 30.7M | 33.3M | 38.3M | 22.7M | |
Net Tangible Assets | 464.4M | 1.5B | 1.2B | 514.7M | 591.9M | 613.2M | |
Net Receivables | 23.4M | 25.3M | 37.0M | 36.9M | 43.2M | 45.3M | |
Short Term Investments | 369.6M | 187.2M | 267.2M | 825.3M | 639.4M | 346.5M | |
Retained Earnings Total Equity | (945.2M) | (631.4M) | (1.3B) | (1.8B) | (1.6B) | (1.6B) | |
Capital Surpluse | 1.4B | 2.1B | 2.3B | 2.4B | 2.7B | 1.5B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Blueprint Medicines Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Blueprint Medicines' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Blueprint Medicines Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Blueprint Medicines Corp Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Complementary Tools for Blueprint Stock analysis
When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |
Is Blueprint Medicines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.82) | Revenue Per Share 4.632 | Quarterly Revenue Growth 0.519 | Return On Assets (0.24) | Return On Equity (0.80) |
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.